SCHEMBL4883834

SCHEMBL4883834

CC(=O)Nc1nc(C=CC(=O)O)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
HSD17B10 Q99714 2/20 0.61
MAPT P10636 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 1/20 0.49
ABL1 P00519 6/20 0.46
NPC1 O15118 3/20 0.44
MAPK1 P28482 1/20 0.44
RAB9A P51151 3/20 0.44
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883820 1.00 KDM4E (0.61) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3939079 0.89 KDM4E (0.53) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3939083 0.89 KDM4E (0.53) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3939082 0.89 KDM4E (0.53) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883404 0.87 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883400 0.87 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883395 0.87 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL15158280 0.85 KDM4E (0.49) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3403632 0.85 KDM4E (0.49) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3403637 0.85 KDM4E (0.49) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015202-A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity ASTELLAS PHARMA INC. (JP) 2008-01-17 US disclosed
EP-1791835-A2 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY Astellas Pharma Inc. (JP) 2007-06-06 EP disclosed
WO-2006028269-A2 THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY ASTELLAS PHARMA INC. (JP) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015202-A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity VCAM1, VAPB, VAPA KDM4E 3463/4885HSD17B10 1895/4885MAPT 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.